However, there is research being carried out to determine if the drug could have applications for this form of diabetes, too, and early results so far have been promising
et al., 2023), suggesting that GLP-1R may influence AD progression by modulating metabolic pathways associated with DM
Zepbound produced average weight loss of up to 20.9% over 72 weeks in a clinical trial of adults without diabetes, but individual outcomes vary, and the medication has important risks and side effects
Visible improvement was noted after four weeks, particularly in skin texture and superficial wrinkles
Are there alternative treatments if my clinician advises against GLP-1 medications (for example, due to personal/family history suggesting MTC/MEN2)